Naphcon, Vasocon (naphazoline ophthalmic) dosing, indications, interactions, adverse effects, and more

Sections

Sections naphazoline ophthalmic
Dosing & Uses
Adverse Effects
Warnings
Pregnancy
Pharmacology
Images
Patient Handout
Formulary

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

ophthalmic solution

OTC: 0.012%
OTC: 0.02%
0.1%

Ocular Vasoconstrictor/Decongestant

Temporary relief of ocular redness caused by irritation & relief of burning or irritation caused by dry eyes

0.1% solution: 1-2 gtt to affected eye q3-4hr PRN

0.012% or 0.025% solution: 1-2 gtt to affected eye(s); not to exceed q6hr; therapy not to exceed 72 hours of use

Dosage Forms & Strengths

ophthalmic solution

OTC: 0.012%
0.03%
0.1%

Ocular Vasoconstrictor/Decongestant

Safety & efficacy not established

Frequency Not Defined

Blurred vision

Mild transient stinging and/or irritation

Mydriasis

Increased or decreased intraocular pressure

Headache

Contraindications

Narrow angle glaucoma

Anatomic narrow angle

Hypersensitivity

Cautions

Use with caution in patients with hypertension, cardiovascular abnormalities, diabetes mellitus, hyperthyroidism, infection, or injury

Rare reports of hypertension, cardiac irregularities, nervousness, nausea, dizziness, weakness, and sweating

Stop use if vision changes, eye pain, condition worsens

Concurrent use with MAO inhibitors may cause hypertensive crisis

Notify health care professional if no improvement after >48hr (72hr if used OTC) or condition worsens

Pregnancy & Lactation

Pregnancy Category: C

Lactation: Not known if excreted in milk; use caution

Pregnant or breastfeeding patients should seek advice of health professional before using OTC drugs

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Mechanism of Action

May produce vasoconstriction by stimulating alpha-adrenergic receptors in the arterioles of the conjunctiva and nasal mucosa

May produce mydriasis when applied to the conjunctiva, but this effect is usually minimal with the concentrations used as ocular decongestants

Pharmcokinetics

Absorption: Minimal (systemic)

Onset: Within 10 min

Duration: 2-6 hr

Images

No images available for this drug.

Patient Handout

A Patient Handout is not currently available for this monograph.

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Create Your List of Plans

Adding plans allows you to:

View the formulary and any restrictions for each plan.
Manage and view all your plans together – even plans in different states.
Compare formulary status to other drugs in the same class.
Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

View explanations for tiers and restrictions

Tier	Description
1	This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2	This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC	NOT COVERED – Drugs that are not covered by the plan.

Code	Definition
PA	Prior Authorization Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL	Quantity Limits Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST	Step Therapy Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR	Other Restrictions Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.

Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.

[CLOSE WINDOW]